1.75
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SAVA?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1.83
Offen:
$1.84
24-Stunden-Volumen:
5.99M
Relative Volume:
4.39
Marktkapitalisierung:
$104.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.22M
KGV:
-1.2681
EPS:
-1.38
Netto-Cashflow:
$-82.44M
1W Leistung:
-12.06%
1M Leistung:
-17.84%
6M Leistung:
-30.00%
1J Leistung:
-90.77%
Cassava Sciences Inc Stock (SAVA) Company Profile
Firmenname
Cassava Sciences Inc
Sektor
Branche
Telefon
512-501-2444
Adresse
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Vergleichen Sie SAVA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SAVA
Cassava Sciences Inc
|
1.75 | 104.83M | 0 | -97.22M | -82.44M | -1.38 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-11-26 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2024-10-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2024-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2022-11-16 | Herabstufung | B. Riley Securities | Buy → Neutral |
2021-07-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2021-07-07 | Bestätigt | Maxim Group | Buy |
2021-04-27 | Eingeleitet | B. Riley Securities | Buy |
2021-02-16 | Bestätigt | H.C. Wainwright | Buy |
2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-09-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-05-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-05-15 | Herabstufung | Maxim Group | Buy → Hold |
2020-01-10 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Cassava Sciences Inc Aktie (SAVA) Neueste Nachrichten
Shareholders Filed a Lawsuit Against Cassava Sciences for Misleading Alzheimer’s Drug Claims - TradingView
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Sold by Cetera Investment Advisers - Defense World
BNP Paribas Financial Markets Buys 55,813 Shares of Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Cassava Sciences, Inc. (NASDAQ:SAVA) Stake Lifted by Northern Trust Corp - Defense World
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha
Cassava Sciences Holds 2025 Annual Meeting, Elects Directors - TipRanks
Transcript : Cassava Sciences, Inc.Shareholder/Analyst Call - marketscreener.com
Cassava Sciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationSAVA - ACCESS Newswire
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025SAVA - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Class Action Filed Against Cassava Sciences, Inc. (SAVA)February 10, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your RightsSAVA - ACCESS Newswire
Cassava Reports Q1 2025 Financials Results, Provides Business Update - GlobeNewswire
Cassava Sciences Shifts Focus to TSC-Related Epilepsy - TipRanks
Cassava Sciences (SAVA) Faces Financial Challenges Amid Strategic Shifts - GuruFocus
Invesco Ltd. Trims Stock Position in Cassava Sciences, Inc. (NASDAQ:SAVA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Cassava Sciences (SAVA) Appoints New SVP of Neuroscience | SAVA Stock News - GuruFocus
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - citybiz
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class ActionSAVA - ACCESS Newswire
Finanzdaten der Cassava Sciences Inc-Aktie (SAVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cassava Sciences Inc-Aktie (SAVA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):